Quetiapine vs Ziprasidone
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.
Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.
Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.
See our Terms of Use and Editorial Policy.
Quetiapine (Seroquel) and ziprasidone (Geodon) are both second-generation (atypical) antipsychotic medications used to treat schizophrenia and bipolar disorder [1][2]. While they share a common therapeutic class, they differ significantly in metabolic side effect profiles — a distinction central to antipsychotic selection.
Quetiapine has broad indications: schizophrenia, bipolar mania, bipolar depression, and adjunctive therapy for major depressive disorder [1]. Ziprasidone is approved for schizophrenia and acute bipolar mania [2].
The key differentiator is metabolic impact. Quetiapine is associated with substantial weight gain and metabolic syndrome risk, while ziprasidone is one of the most metabolically neutral atypical antipsychotics [2][3]. However, ziprasidone carries a unique cardiac consideration — QTc prolongation [2].
Quetiapine vs Ziprasidone: Side-by-side comparison
| Category | Quetiapine | Ziprasidone |
|---|---|---|
| Drug Class | Atypical antipsychotic | Atypical antipsychotic |
| Generic Name | Quetiapine fumarate | Ziprasidone HCl |
| Brand Name | Seroquel, Seroquel XR | Geodon |
| FDA Approved For | Schizophrenia, bipolar mania/depression, adjunct MDD | Schizophrenia, bipolar mania |
| How It Works | D2, 5-HT2A, H1, adrenergic antagonist | D2, 5-HT2A antagonist; 5-HT1A partial agonist |
| Dosage Forms | Tablets IR/XR (25-400 mg) | Capsules (20-80 mg), IM injection |
| Typical Dose | 300-800 mg/day | 40-80 mg twice daily with food |
| Common Side Effects | Sedation, weight gain, dry mouth | Nausea, akathisia, dizziness |
| Weight Gain | Moderate-high (avg 2-5 kg) | Minimal (avg 0-1 kg) |
| Metabolic Risk | High (dyslipidemia, hyperglycemia) | Low |
| QTc Prolongation | Minimal | Significant (~20 ms) |
| Cost (Generic) | $15-$40/month | $15-$45/month |
Efficacy: How well does each drug work?
The CATIE study included both medications [3]. In Phase 1, quetiapine and ziprasidone showed similar overall efficacy for schizophrenia, though both had higher discontinuation rates than olanzapine.
Quetiapine demonstrates efficacy across a broader range. For bipolar depression, it is one of the few antipsychotics with FDA approval, based on the BOLDER trials [1]. Ziprasidone does not have this indication [2]. For acute mania, both are effective [1][2].
Quetiapine at low doses (25-100 mg) is widely used off-label for insomnia due to histamine H1 antagonism, though this carries metabolic risks [1].
Side effects comparison
Metabolic effects represent the most significant safety difference [1][2][3].
Quetiapine causes moderate to high weight gain (avg 2-5 kg), with risk of dyslipidemia, hyperglycemia, and new-onset type 2 diabetes [1][3]. Metabolic monitoring is FDA-required [1].
Ziprasidone is associated with minimal weight gain (avg 0-1 kg) and a benign metabolic profile [2][3]. In CATIE, ziprasidone patients actually lost weight [3].
Ziprasidone's primary concern is QTc prolongation (~20 ms). It is contraindicated in patients with known QT prolongation, recent MI, or uncompensated heart failure [2]. ECG monitoring is recommended.
Quetiapine commonly causes sedation, orthostatic hypotension, dry mouth, and constipation [1]. Ziprasidone is less sedating but may cause akathisia and nausea, particularly without food [2].
Cost comparison
Convenience and dosing
Quetiapine is dosed once daily (XR) or twice daily (IR), with bedtime dosing practical due to sedation [1]. Ziprasidone must be taken twice daily with food (at least 500 calories) — bioavailability drops ~50% without food [2]. This food requirement affects adherence. Ziprasidone is also available as IM injection for acute agitation [2].
Which is right for you?
Quetiapine may be preferred for bipolar depression, patients needing sedation, and broader mood stabilization — but metabolic monitoring is essential [1]. Ziprasidone may be preferred for patients concerned about weight gain, those with metabolic syndrome or diabetes [2][3]. Cardiac history must be evaluated before starting ziprasidone.
This information is for educational purposes only. Antipsychotic selection should be made with your psychiatrist.
Frequently asked questions
References
- [Regulatory] Quetiapine fumarate (Seroquel) prescribing information. AstraZeneca. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020639s075lbl.pdf Accessed 2025-06-15.
- [Regulatory] Ziprasidone HCl (Geodon) prescribing information. Pfizer. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020825s060lbl.pdf Accessed 2025-06-15.
- [Regulatory] Lieberman JA, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia (CATIE). N Engl J Med. 2005;353(12):1209-1223. https://doi.org/10.1056/NEJMoa051688 Accessed 2025-06-15.
- [Observational] GoodRx price comparison: quetiapine and ziprasidone. https://www.goodrx.com Accessed 2025-06-15.
Written and fact-checked by PrescriptionDrugs.org Editorial Team
Last updated: